Abstract

INTRODUCTION: We aimed to investigate serum galanin-like peptide (GALP) levels and their correlation with hormonal and metabolic parameters in patients with polycystic ovary syndrome (PCOS).
MATERIAL AND METHODS: The study included 48 women (age range, 18–44 years) with a diagnosis of PCOS, and a control group that included 40 healthy females (age range, 18–46 years). Waist circumference, body mass index (BMI), and Ferriman-Gallwey score were evaluated and plasma glucose, lipid profile, oestradiol, progesterone, total testosterone, prolactin, insulin, dehydroepiandrosterone sulphate (DHEA-S), follicle-stimulating hormone (FSH), luteinizing hormone (LH), thyroid-stimulating hormone (TSH), 25-hydroxyvitamin D (25(OH)D), fibrinogen, d-dimer, C-reactive protein (CRP), and GALP levels were measured in all study subjects.
RESULTS: Waist circumference (p = 0.044) and Ferriman-Gallwey score (p = 0.002) were significantly higher in patients with PCOS compared to the control group. Among the metabolic and hormonal parameters studied, only total testosterone was significantly higher in patients with PCOS (p = 0.002). Also, the serum 25(OH)D level was significantly lower in the PCOS group (p = 0.001). CRP, fibrinogen, and D-dimer levels were all similar between the 2 groups. Serum GALP level was significantly higher in PCOS patients (p = 0.001). GALP was negatively correlated with 25(OH)D (r = –0.401, p = 0.002) and positively correlated with total testosterone values (r = 0.265, p = 0.024). Multiple regression analysis revealed that both total testosterone and 25(OH)D significantly contributed to GALP levels.
CONCLUSIONS: Our study is the first in the literature to evaluate serum GALP levels in patients with PCOS. Increased GALP levels in PCOS and its association with total testosterone levels might show that GALP can act as an intermediary in increased GnRH-mediated LH release, which is one of the underlying pathogenetic mechanism of PCOS.

Details

Title
Galanin-like peptide and its correlation with androgen levels in patients with polycystic ovary syndrome
Author
Demirpence, Mustafa 1   VIAFID ORCID Logo  ; Yilmaz Yasar, Hamiyet 2   VIAFID ORCID Logo  ; Karakoyun, Inanc 3   VIAFID ORCID Logo  ; Girgin, Elif Merve 3   VIAFID ORCID Logo 

1  Department of Endocrinology and Metabolic Diseases, Health Sciences University, Izmir Tepecik Training and Research Hospital, Izmir, Türkiye. [email protected] 
2  Department of Endocrinology and Metabolic Diseases, Health Sciences University, Izmir Tepecik Training and Research Hospital, Izmir, Türkiye 
3  Department of Medical Biochemistry, Health Sciences University, Izmir Tepecik Training and Research Hospital, Izmir, Türkiye 
First page
197
End page
202
Publication year
2023
Publication date
2023
Publisher
Wydawnictwo Via Medica
ISSN
0423104X
Source type
Scholarly Journal
Language of publication
English
DOI
https://doi.org/10.5603/EP.a2023.0026
ProQuest document ID
2810935732
Copyright
© 2023. This work is published under https://creativecommons.org/licenses/by-nc-nd/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.